Bpifrance

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

EG 427 is a French biotechnology company specializing in gene therapy. It pioneers 'pinpoint gene therapy', focusing on HSV-1-based vectors to treat severe, chronic, and localized diseases, with an initial focus on neurogenic bladder disorders resulting from spinal cord injuries.

Ochy is a mobile application that uses video analysis and AI to evaluate users' running technique, identify areas for improvement, and provide personalized exercise plans to prevent injuries and enhance performance.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Primaa is a MedTech company that provides an AI-powered platform for automated cancer diagnosis. Through image analysis and deep learning, the software enhances the detection of cancer biomarkers and supports personalized treatment decisions. It offers digital histology capabilities that digitize tissue slides, aggregate images in a database, and enable digital identification of tissue anomalies. The platform aims to increase diagnostic accuracy and throughput while maintaining consistent reliability across histological assessments.

Doado is a health technology company that specializes in developing mobile applications for back health management. Its primary product is an e-health application designed to guide users step by step in improving their back health and preventing Musculoskeletal Disorders. The application offers personalized video programs, expert advice from physiotherapists and doctors, and AI-driven progress tracking, enabling individuals and companies to maintain an active lifestyle and reduce the risk of chronic back pain.

Fudzs specializes in sustainable bioeconomy, developing eco-friendly cell bioproduction processes using cutting-edge bioreactor technology. By integrating advanced biomaterial engineering with cellular science, Fudzs enables mass production of cells at reduced costs, opening new market opportunities.

Founded in 2016, Vaxinano is a biotechnology company dedicated to the preclinical and pharmaceutical development of human and veterinary vaccines. It specializes in creating vaccines and drug delivery systems that selectively target difficult pathogens like parasites, viruses, or bacteria.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Hepta Medical develops a microwave ablation platform designed for minimally invasive, nonsurgical treatment of early lung cancer. Its proprietary technology features an ablation catheter with integrated temperature sensing, enabling real-time monitoring and control of tissue ablation size.

Enalees develops molecular diagnostic tests for animals that can be used directly by veterinarians, enabling rapid on-site detection of infectious diseases in pets and livestock. The company provides fast, easy-to-use diagnostic kits with integrated reagents and a portable reader, designed for use in clinics and field settings to support timely and accurate treatment decisions.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Klineo is a healthcare platform focused on enhancing access to clinical trials for oncology patients. It features an intuitive and intelligent search interface that caters to both healthcare professionals and patients. The platform allows users to efficiently locate relevant clinical trials for specific conditions such as breast, skin, and lymphoma cancers, facilitating contact with trial centers and improving the overall trial search experience. By connecting patients and doctors with appropriate clinical research opportunities, Klineo aims to streamline the process of finding critical treatment options in the oncology field.

Pixacare is a medical imaging platform that converts smartphones into secure documentation tools for wound care. The app enables healthcare professionals to capture, manage, and monitor wound images and associated data, integrating with patient administration systems and electronic health records to streamline workflows. It supports home-care staff, surgeons, and dermatologists in monitoring chronic and post-surgical wounds, predicting complications, and saving time on visual assessments. The solution is CE-marked as a Class I digital medical device and is hosted on certified health data infrastructure to ensure data security and interoperability with healthcare IT systems.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell specializes in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research labs. Utilizing non-ionizing, three-dimensional MRI technology adapted for diverse animal morphologies, the company offers sustainable systems enhanced by artificial intelligence algorithms to provide precise and insightful animal healthcare services.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

Founded in 2017, Pixee Medical specializes in manufacturing medical equipment that aids in precise implant positioning. Utilizing computer vision and AI technologies, their camera-based systems enable surgeons to navigate prostheses with millimeter precision using smart glasses, enhancing orthopedic surgery affordability.

AQEMIA is a pharmaceutical technology company specializing in drug discovery. It employs a proprietary platform that integrates quantum-inspired physics with machine learning algorithms to accelerate and enhance the identification of new drug candidates tailored to specific therapeutic targets. This innovative approach enables AQEMIA to generate a robust pipeline of novel drug leads, aiming to improve efficiency and accuracy in predicting the affinity between drug candidates and their intended targets.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Ochy is a mobile application that uses video analysis and AI to evaluate users' running technique, identify areas for improvement, and provide personalized exercise plans to prevent injuries and enhance performance.

HUVY employs artificial intelligence to optimize dermatological treatment pathways and deliver critical medical information in real-time.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

BariaTek is a company specializing in innovative bariatric surgery solutions. It focuses on providing minimally invasive procedures that utilize trans-oral access techniques and implantable devices through endoscopy. By doing so, BariaTek aims to replicate the effects of traditional bariatric surgery while minimizing patient discomfort and recovery time. This approach allows patients to receive effective treatment for obesity and related diseases in a less invasive manner, thereby enhancing the overall patient experience and outcomes.

EverImmune specializes in developing live biotherapeutic products designed to enhance the efficacy of immunotherapy for cancer patients. Its flagship product, Oncobax®, aims to restore responsiveness to immune checkpoint inhibitors by leveraging gut microbiota.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Founded in 2007, Microoled specializes in the design, production, and marketing of OLED microdisplays for near-eye applications. These displays are used in outdoor optical equipment, night vision glasses, medical devices, and augmented reality (AR) glasses.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

Gleamer develops AI-powered radiology software that acts as an automated second reader within clinicians' standard imaging workflows. Its AI companions automatically detect bone abnormalities and lesions on X-ray exams, highlighting findings and providing preliminary data to support diagnoses, speeding interpretation and helping radiologists prioritize patients. The tools integrate into routine reading environments and are deployed across multiple countries and institutions to improve diagnostic accuracy and efficiency in trauma and general radiography.

Numa Health is a medical bioinformatics health technology company that focuses on empowering individuals to optimize their health capital and well-being. It has developed a digital health platform that offers tools designed to enhance users' commitment to their health. This platform facilitates the reinterpretation of blood test results, providing insights into bodily functions and overall health. By enabling users to measure, understand, and take actionable steps regarding their health, Numa Health aims to support individuals in their journey towards better health management.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Maddie provides patient and practice management software for physiotherapists and other health professionals. It operates a healthcare platform that helps practitioners manage their practices by offering digital diaries, online appointment bookings, and a customizable and well-referenced website, enabling users to structure waiting lists, optimize schedules, and efficiently handle incoming requests.

Kairos Discovery is a biotechnology company focused on developing novel targeted cancer therapies. Its mission is to create innovative medicinal chemistry solutions that aim to transform the lives of cancer patients.

Santé Académie is an innovative online training platform dedicated to enhancing the skills of healthcare professionals. Recognizing the evolving roles of caregivers and the rapid pace of medical knowledge advancement, the company offers high-quality educational videos accessible via web or mobile. Each course is structured into brief episodes lasting 5 to 15 minutes, catering to the busy schedules of doctors, nurses, pharmacists, and care assistants. The curriculum covers essential clinical and regulatory subjects relevant to daily practice, ensuring that participants receive up-to-date information. The courses are certified by the ANDPC and produced by leading experts from esteemed institutions. With a focus on continuous education and engagement, Santé Académie aims to improve patient care throughout the healthcare continuum, a mission supported by over 20,000 professionals and health institutions, including notable organizations such as GHU Paris psychiatrie & neurosciences and Service de Santé des Armées.

Deemea develops an AI-driven platform for clinical research, streamlining imaging data management. Its integrated copilot ensures efficiency and reliability in data processing.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Kiro develops an AI-powered digital health platform that enhances the relevance of lab test results for healthcare professionals and patients. Its tool provides personalized, understandable interpretations of medical biology reports using artificial intelligence to aid clinical decision-making, engage patients, and improve healthcare outcomes.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Previa Medical operates a real-time health technology platform that analyzes patient data directly from electronic health records in hospitals. It identifies complication risks and enables healthcare professionals to provide timely treatment, potentially improving patient outcomes.

Previa Medical operates a real-time health technology platform that analyzes patient data directly from electronic health records in hospitals. It identifies complication risks and enables healthcare professionals to provide timely treatment, potentially improving patient outcomes.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, dedicated to developing innovative solutions for chronic pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a personal endorphin stimulator that facilitates on-demand stimulation of the body’s natural endorphins to alleviate pain. Drawing on a decade of pre-clinical and clinical research, Remedee Labs aims to improve the quality of life for the 1.5 billion people worldwide suffering from chronic pain, particularly focusing on conditions such as fibromyalgia. By collaborating with medical practitioners, the company offers a patient-centered digital service platform that enhances the accessibility and effectiveness of endorphin-stimulation therapy for personal healthcare. As it continues to evolve, Remedee Labs plans to expand its platform to address additional chronic pain conditions, positioning itself as a leader in neuromodulation technology for pain management.

Jalon Therapeutics is a biotechnology company focused on developing cancer therapies by inactivating essential tumor signaling pathways through disruption of protein-protein interactions. The company aims to identify novel therapeutic targets, including through non-oncogene addiction, and to develop anticancer treatment strategies that advance patient outcomes.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

MOTEN Technologies specializes in muscle sensors technology, offering real-time monitoring of muscular effort and fatigue through vibration analysis. Their platform aims to prevent musculoskeletal disorders (MSDs) by providing data-driven insights for companies to enhance employee health and safety.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in inflammation resolution, aiming to inhibit specific processes in the early stages of inflammation and the recruitment of innate immune cells. By leveraging monoclonal antibodies, Thabor Therapeutics seeks to provide effective solutions for healthcare providers to treat patients suffering from these conditions.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

Ludocare is a company focused on developing therapeutic robots aimed at assisting patients with chronic diseases and their families. Its innovative devices are designed to complement traditional drug treatments by providing personalized support that empowers patients, particularly children, to enhance their treatment compliance and overall quality of life. By improving patients' abilities and autonomy, Ludocare's solutions seek to foster better disease management and stabilization of essential treatments, ultimately aiming to improve the efficiency of healthcare delivery for those affected by chronic conditions.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops AI-powered medical imaging software that transforms standard 2D scans into 3D reconstructions of arterial systems, enabling early detection of cardiovascular and neurovascular conditions such as aneurysms. The solution automates quantitative image analysis, providing accurate, operator-independent assessments that integrate seamlessly into hospital workflows. By allowing clinicians to monitor structural changes over time, the platform supports precise and reliable diagnoses for vascular surgeons and other healthcare professionals.

Osivax develops immunotherapy vaccines designed to enhance the body's immune response against infectious diseases. Their vaccines aim to expedite uptake into dendritic cells and increase immunogenicity of natural proteins, triggering a more effective immune response, including CD8 T cell activation. This enables medical practitioners to treat patients with conditions such as cancer, influenza, malaria, and other infectious diseases.

Intradys develops medical software technologies for interventional neuroradiology. It creates algorithms that fuse machine learning with mixed reality to help clinicians determine optimal strategies based on patient factors such as age and prior history, and the suitability of devices to the pathology. The software relies on imaging acquired before and during procedures to enable neuroradiologists to make informed decisions in the operating room.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Implicity develops a software-as-a-service remote monitoring platform for patients with connected pacemakers and defibrillators. The platform collects and analyzes data from cardiac electronic implants, using an artificial intelligence module to sort and summarize information and assess the criticality of alerts within the patient’s medical context. This enables cardiology and other healthcare professionals to automate remote monitoring, consolidate patient telemetry on a single platform, and support timely clinical decision-making to deliver high-quality care.

Mobee Travel operates an online platform specializing in accessible vacation bookings for individuals with disabilities. It offers over 30,000 verified accommodations worldwide and provides medical equipment upon request.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Vaxxel is a biotechnology company focused on developing live-attenuated vaccines. Its innovative platform aims to create novel vaccines targeting critical respiratory diseases such as bronchiolitis and pneumonia, specifically caused by human metapneumovirus.

Doctolib is an online healthcare platform and management software provider based in Paris. The company offers a patient-facing service that enables users to find nearby health practitioners and book appointments 24/7, and a practitioner-focused software suite that helps clinics manage bookings, organize patient consultations, and reduce missed appointments. Founded in 2013, Doctolib serves a range of medical specialties and aims to improve access to care while increasing efficiency for doctors and clinics, contributing to better work-life balance for practitioners and more convenient care for patients.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Susu delivers comprehensive health services to families in the African diaspora, spanning preventive care, medical treatments, chronic disease management, and access to authentic medications. Through a bundled, long-term care offering, Susu enables planned health support, regular monitoring of conditions such as pregnancy and chronic diseases, and connects users to quality healthcare services and insurance options, with a focus on affordability and accessibility.

Susu delivers comprehensive health services to families in the African diaspora, spanning preventive care, medical treatments, chronic disease management, and access to authentic medications. Through a bundled, long-term care offering, Susu enables planned health support, regular monitoring of conditions such as pregnancy and chronic diseases, and connects users to quality healthcare services and insurance options, with a focus on affordability and accessibility.

Founded in 2017 and based in Toulouse, France, Cell-Easy operates as a stem cell Contract Development and Manufacturing Organization (CDMO). It specializes in providing ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical development projects.

NaoX Technologies is a company focused on the prevention of neurological disorders through innovative technology. It develops wireless headphones equipped with integrated sensors that passively monitor brain vibrations to record electroencephalogram data in real time. This data is then aggregated and presented on a software dashboard for healthcare providers, facilitating better diagnosis and treatment for patients. The company's mission is to democratize access to neurological disorder prevention, aiming to enhance patient outcomes and support recovery from mental illness.

Cureety is a healthcare technology company offering a telemedicine and telemonitoring platform for remote patient follow-up, with a focus on oncology. The platform collects patient-reported outcomes, applies clinical algorithms tailored to different treatments, and provides personalized support services to patients. By enabling remote monitoring, Cureety helps healthcare professionals prioritize care for vulnerable patients and improve the quality of cancer care.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

Diaccurate is a biotechnology company based in Paris, France, founded in 2012. The company focuses on researching and developing innovative treatments for various medical conditions, including HIV infection, endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring new frontiers in oncology to create novel therapeutic approaches aimed at combating difficult-to-treat cancers and improving patient outcomes.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Depixus specializes in advanced genomic analysis technology. Its innovative platform enables real-time, high-precision analysis of individual biomolecular interactions at scale. This allows researchers to uncover new biological pathways and disease mechanisms, facilitating the development of precision medicines.

Spartha Medical is a medical technology company focused on developing innovative coatings designed to enhance the safety of medical devices and consumer products. The company utilizes eco-friendly and biocompatible coatings made from natural biopolymers, which possess antibacterial, antiviral, and anti-inflammatory properties. Their patented technology allows for precise control over the assembly of two distinct polyelectrolytes, enabling the creation of versatile and multifunctional surface coatings tailored to specific applications. By providing effective solutions that protect users from microbial and inflammatory risks, Spartha Medical aims to improve healthcare outcomes and promote safer use of medical devices across various healthcare settings.